These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10446950)

  • 1. The relationship of untreated borderline infiltrates by the Banff criteria to acute rejection in renal allograft biopsies.
    Meehan SM; Siegel CT; Aronson AJ; Bartosh SM; Thistlethwaite JR; Woodle ES; Haas M
    J Am Soc Nephrol; 1999 Aug; 10(8):1806-14. PubMed ID: 10446950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Borderline Changes on Dysfunctional Renal Allograft Biopsies: Clinical Relevance in a Living Related Renal Transplant Setting.
    Mubarak M; Shakeel S; Abbas K; Aziz T; Zafar MN; Naqvi SA; Rizvi SA
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):24-27. PubMed ID: 28260426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of eosinophils in suspicious or borderline renal allograft biopsies.
    Emovon OE; King JA; Smith SR; Op't Holt C; McDonald F; Howell DN; Browne BJ
    Clin Nephrol; 2003 May; 59(5):367-72. PubMed ID: 12779099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of the Banff borderline biopsy.
    Schweitzer EJ; Drachenberg CB; Anderson L; Papadimetriou JC; Kuo PC; Johnson LB; Klassen DK; Hoehn-Saric E; Weir MR; Bartlett ST
    Am J Kidney Dis; 1996 Oct; 28(4):585-8. PubMed ID: 8840950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies.
    Woodle ES; Cronin D; Newell KA; Millis JM; Bruce DS; Piper JB; Haas M; Josephson MA; Thistlethwaite JR
    Transplantation; 1996 Oct; 62(7):906-10. PubMed ID: 8878382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the Banff classification of early renal allograft biopsies and correlation with outcome.
    Bates WD; Davies DR; Welsh K; Gray DW; Fuggle SV; Morris PJ
    Nephrol Dial Transplant; 1999 Oct; 14(10):2364-9. PubMed ID: 10528659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of renal allograft biopsies with "borderline changes," as defined in the Banff Schema.
    Saad R; Gritsch HA; Shapiro R; Jordan M; Vivas C; Scantlebury V; Demetris AJ; Randhawa PS
    Transplantation; 1997 Oct; 64(7):992-5. PubMed ID: 9381547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance biopsies are superior to functional studies for the diagnosis of acute and chronic renal allograft pathology in children.
    Birk PE; Stannard KM; Konrad HB; Blydt-Hansen TD; Ogborn MR; Cheang MS; Gartner JG; Gibson IW
    Pediatr Transplant; 2004 Feb; 8(1):29-38. PubMed ID: 15009838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies.
    Meehan SM; Domer P; Josephson M; Donoghue M; Sadhu A; Ho LT; Aronson AJ; Thistlethwaite JR; Haas M
    Hum Pathol; 2001 Feb; 32(2):205-15. PubMed ID: 11230708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of Banff score of early kidney allograft biopsies for 1-year graft survival.
    Kaminska D; Bernat B; Mazanowska O; Krasnowski R; Polak W; Patrzalek D; Kochman A; Klinger M
    Transplant Proc; 2006; 38(1):59-61. PubMed ID: 16504664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization.
    Randhawa PS; Saad RS; Jordan M; Scantlebury V; Vivas C; Shapiro R
    Transplantation; 1999 Jan; 67(1):85-9. PubMed ID: 9921801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Serial Protocol Biopsies Performed After 1 Year in Predicting Long-Term Kidney Allograft Function According to Histologic Phenotype.
    Zachariah MS; Dwivedi AK; Yip CS; Chang SS; Gundroo A; Venuto RC; Tomaszewski J; Patel SK; Sharma R
    Exp Clin Transplant; 2018 Aug; 16(4):391-400. PubMed ID: 29206090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Banff borderline acute rejection among renal allograft recipients.
    Matoza JR; Danguilan RA; Chicano S
    Transplant Proc; 2008 Sep; 40(7):2303-6. PubMed ID: 18790219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of borderline infiltrates with minimal inflammation in kidney transplant recipients has no effect on allograft or patient outcomes.
    Dale LA; Brennan C; Batal I; Morris H; Jain NG; Valeri A; Husain SA; King K; Tsapepas D; Cohen D; Mohan S
    Clin Transplant; 2020 Sep; 34(9):e14019. PubMed ID: 32573811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA fragmentation in acute and chronic rejection after renal transplantation.
    Ott U; Aschoff A; Fünfstück R; Jirikowski G; Wolf G
    Transplant Proc; 2007; 39(1):73-7. PubMed ID: 17275477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of steroid-free low concentration calcineurin inhibitor maintenance immunosuppression regimen on renal allograft histopathology and function.
    Nainani N; Patel N; Tahir N; Kumar R; Weber-Shrikant E; Gundroo AA; Murray BM; Tornatore KM; Blessios GA; Venuto RC
    Nephrol Dial Transplant; 2012 May; 27(5):2077-83. PubMed ID: 22058172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infiltrates in protocol biopsies from renal allografts.
    Mengel M; Gwinner W; Schwarz A; Bajeski R; Franz I; Bröcker V; Becker T; Neipp M; Klempnauer J; Haller H; Kreipe H
    Am J Transplant; 2007 Feb; 7(2):356-65. PubMed ID: 17283485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group.
    Solez K; Vincenti F; Filo RS
    Transplantation; 1998 Dec; 66(12):1736-40. PubMed ID: 9884269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Borderline rejection after renal transplantation--to treat or not to treat.
    Beimler J; Zeier M
    Clin Transplant; 2009 Dec; 23 Suppl 21():19-25. PubMed ID: 19930312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.